AWA
KRYS icon

Acumen Wealth Advisors’s Krystal Biotech KRYS Stock Holding History

Acumen Wealth Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Sell
27
-7
-21% -$2.09K ﹤0.01% 326
2026
Q1 		$8.78K Hold
34
– – ﹤0.01% 322
2025
Q4 		$8.38K Buy
+34
New +$7.16K ﹤0.01% 323

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acumen Wealth Advisors's KRYS Position: Q2 2026 in Review

Acumen Wealth Advisors reduced its Krystal Biotech (KRYS) stake by 21% in Q2 2026, selling an estimated $2.09K and leaving 27 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #326.

Acumen Wealth Advisors first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 421 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Acumen Wealth Advisors held 27 shares of Krystal Biotech worth $10K as of Q2 2026.
  • Acumen Wealth Advisors sold 7 Krystal Biotech shares in Q2 2026, an estimated $2.09K.
  • Krystal Biotech made up ﹤0.01% of Acumen Wealth Advisors's portfolio in Q2 2026, its #326 holding.
  • Acumen Wealth Advisors first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 421 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Acumen Wealth Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.